Skip to main content
SpringerLink
Log in

Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users

  • Original Articles
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Breast cancer tumors occurring in hormone replacement therapy (HRT) users are less aggressive, but no studies have compared tumor aggressiveness among HRT users by length and mode of therapy.

Methods

A total of 1105 consecutive postmenopausal patients treated for operable breast cancer at the European Institute of Oncology were identified. Women exposed to HRT were compared with HRT nonusers by clinical stage at presentation and pathologic and biological tumor characteristics. HRT duration and administration modality were analyzed in relation to tumor characteristics in the HRT group.

Results

Better stage distribution, including smaller pathologic tumor diameter and fewer involved axillary lymph nodes, was seen in the HRT group. Estrogen receptor-positive tumors were more frequent in the control group, but this tendency was reversed with longer exposure to HRT. Histological grade III tumors were less frequent in the HRT group. More favorable prognostic factors were associated with HRT >5 years. The proliferative fraction was higher in patients with exposure <1 vs. >5 years and in oral versus transdermal users.

Conclusions

Breast cancers developing during HRT have better prognostic characteristics than those seen in HRT nonusers. A trend toward better prognostic characteristics with increasing duration of HRT was seen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality.N Engl J Med 1997;336:1769–75.

    Article  PubMed  CAS  Google Scholar 

  2. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormoen replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer.Lancet 1997;350:1047–59.

    Article  Google Scholar 

  3. Histological Typing of Breast Tumours (International Histological Classification of Tumours, No. 2). 2nd ed. Geneva: World Health Organization, 1981.

  4. Rosen PP, Oberman HA.Tumors of the Mammary Gland. Washington, DC: Armed Forces Institute of Pathology, 1993.

    Google Scholar 

  5. Elston, CW, Ellis IO. Pathological prognostic factors in breast cancer: the value of histological grade in breast cancer.Histopathology 1991;19:403–10.

    PubMed  CAS  Google Scholar 

  6. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.J Histochem Cytochem 1981;29:577–80.

    PubMed  CAS  Google Scholar 

  7. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma.Am J Surg Pathol 1996;20:1037–46.

    Article  PubMed  CAS  Google Scholar 

  8. Molino A, Micciolo R, Turazza M, et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis.Int J Cancer 1997;74:433–7.

    Article  PubMed  CAS  Google Scholar 

  9. La Vecchia C, Negri E, Franceschi S, et al. Hormone replacement treatment and breast cancer risk: a cooperative Italian study.Br J Cancer 1995;72:244–8.

    PubMed  Google Scholar 

  10. Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I. Prognostic characteristics in breast cancers after hormone replacement therapy.Breast Cancer Res Treat 1996;38:325–34.

    Article  PubMed  CAS  Google Scholar 

  11. Holli K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy.J Clin Oncol 1998;16:3115–20.

    PubMed  CAS  Google Scholar 

  12. Willis DB, Calle EE, Miracle-McMahill H, et al. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States.Cancer Causes Contro 1996;7:449–57.

    Article  CAS  Google Scholar 

  13. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with favorable histology.JAMA 1999;281:2091–7.

    Article  PubMed  CAS  Google Scholar 

  14. McLeskey SW, Tobias CA, Vezza PR, Filie AC, Kern FG, Hanfelt J. Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor.Am J Pathol 1998;153:1993–2006.

    PubMed  CAS  Google Scholar 

  15. Prall OW, Rogan EM, Sutherland RL. Estrogen regulation of cell cycle progression in breast cancer cellsJ Steroid Biochem Mol Biol 1998;65:169–74.

    Article  PubMed  CAS  Google Scholar 

  16. Bonnier P, Bessenay F, Sasco AJ, et al. Impact of menopausal hormone replacement therapy on clinical and laboratory characteristics of breast cancer.Int J Cancer 1998;79:278–82.

    Article  PubMed  CAS  Google Scholar 

  17. Clark GM, Harvey JM, Osborne CK, Allred DC. Estrogen receptor status (ER) determined by immunohistochemistry (IHC) is superior to biochemical ligand-binding (LB) assay for evaluating breast cancer patients [Abstract].Proc Am Soc Clin Oncol 1997;16:129a.

    Google Scholar 

  18. Wrange O, Nordenskjold B, Gstafsson JA. Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel.Ann Biochem 1978;85:461–75.

    Article  CAS  Google Scholar 

  19. Luqmani YA, Temmim L, Memon A, Ali MA, Parkar AH. Steroid receptor measurement in breast cancers: comparison between ligand binding and enzyme-immunoassay in cytosolic and nuclear extracts.Int J Cancer 1997;71:526–38.

    Article  PubMed  CAS  Google Scholar 

  20. Barbareschi M, Dalla Palma P, Vevilacqua P, et al. Invasive node-negative breast cancer: multivariate analysis of the prognostic value of peritumoral vessel invasion compared with that of conventional clinico-pathologic features.Anticancer Res 1994;14:2229–35.

    PubMed  CAS  Google Scholar 

  21. Lauria R, Perrone F, Carlomagno C, et al. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer.Cancer 1995;76:1772–8.

    Article  PubMed  CAS  Google Scholar 

  22. Mathoulin-Portier MP, Meynard P, Charton-Bain MC, et al., Peritumoral vascular invasion in women with node-negative breast cancer, receiving no adjuvant therapy.Anticancer Res. 1999;19:843–7.

    PubMed  CAS  Google Scholar 

  23. Hirvonen E, Lamberg-Allardt C, Lankinen KS, Geurts P, Wilen-Rosenqvist G. Transdermal oestradiol gel in the treatment of the climacterium: a comparison with oral therapy.Br J Obstet Gynaecol 1997;104:19–25.

    PubMed  CAS  Google Scholar 

  24. Rozenbaum H, Birkhäuser MH. First European Consensus Conference on the Menopause: consensus propositionsMenopause Rev 1997;1:29–36.

    Google Scholar 

  25. Cheang A, Sitruk-Ware R, Samsioe G. Transdermal oestradiol and cardiovascular risk factors.Br J Obstet Gynaecol 1994;101:571–81.

    PubMed  CAS  Google Scholar 

  26. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen.Ann Intern Med 1992;117:1–9.

    PubMed  CAS  Google Scholar 

  27. Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D, Bondy CA. Growth hormone treatment induces mammary gland hyperplasia in ageing primates.Nat Med 1997;3:1141–4.

    Article  PubMed  CAS  Google Scholar 

  28. Pollak M, Constantino J, Polychronakos C, et al. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients.J Natl Cancer Inst 1990;82:1693–7.

    Article  PubMed  CAS  Google Scholar 

  29. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.Lancet 1998;351:1393–6.

    Article  PubMed  CAS  Google Scholar 

  30. Westley BR, May FEB. Role of insulin-like growth factors in steroid modulated proliferation.J Steroid Biochem Mol Biol 1994; 51:1–9.

    Article  PubMed  CAS  Google Scholar 

  31. Goodman-Gruen D, Barrett-Connor E. Effect of estrogen replacement on insulin-like growth factor-1 in postmenopausal women: the Rancho Bernardo Study.J Clin Endocrinol Metab 1996;81: 4268–71.

    Article  PubMed  CAS  Google Scholar 

  32. Carmina E, Lo Dico G, Carollo F, Stanczyk FZ, Lobo RA. Serum IGF-I and binding proteins 1 and 3 in postmenopausal women and the effects of estrogen.Menopause 1996;3:85–9.

    Google Scholar 

  33. Helle SI, Omsio IH, Cwyfan Hughes SC, et al. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study.Clin Endocrinol 1996;45:727–32.

    Article  CAS  Google Scholar 

  34. Campagnoli C, Biglia N, Peris C, Sismondi P. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause.Gynecol Endocrinol 1995;9:67–74.

    Article  PubMed  CAS  Google Scholar 

  35. Campagnoli C, Biglia N, Altare F et al. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor I, growth hormone and sex hormone binding globulin serum levels.Gynecol Endocrinol 1993;7:251–8.

    Article  PubMed  CAS  Google Scholar 

  36. Campagnoli C, Biglia N, Cantamessa C, Lesca L, Lotano MR, Sismondi P. Insulin-like growth factor I (IGF-I) serum level modification during transdermal oestradiol treatment in postmenopausal women: a possible bimodal effect depending on basal IGF-I values.Gynecol Endocrinol 1998;12:259–66.

    PubMed  CAS  Google Scholar 

  37. Steingold KA, Matt DW, DeZiegler D, Sealey JE, Fratkin M, Reznikov S. Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure.J Clin Endocrinol Metab 1991;73:275–80.

    Article  PubMed  CAS  Google Scholar 

  38. Setnikar I, Rovati LC, Vens-Cappell B, Hilgenstock C. Pharmacokinetics of estradiol and of estrone during repeated trandermal or oral administration of estradiol.Arzneimittelforschung 1996;46:766–73.

    PubMed  CAS  Google Scholar 

  39. Lippert TH, Seeger H, Mueck AO. Estradiol metabolism during oral and transdermal estradiol replacement therapy in postmenopausal women.Horm Metab Res 1998;30:598–600.

    Article  PubMed  CAS  Google Scholar 

  40. Gambrell RD Jr. Update on hormone-replacement therapy.Am Fam Physician 1992;46:87–96.

    Google Scholar 

  41. Harding C, Knox WF, Faragher EB, Baildam A, Bundred NJ. Hormone-replacement therapy and tumor grade in breast cancer: prospective study in screening unit.BMJ 1996;312:1646–7.

    PubMed  CAS  Google Scholar 

  42. Strickland DM, Gambrell RD Jr, Butzin CA, Strickland K. The relationship between breast cancer survival and prior post-menopausal estrogen use.Obstet Gynecol 1992;80:400–4.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., MRI-1026, 10021, New York, NY

    Virgilio Sacchini MD

  2. Breast Department, European Institute of Oncology, Milan, Italy

    Stefano Zurrida MD, Gisella Andreoni MD, Alberto Luini MD, Viviana Galimberti MD, Paolo Veronesi MD, Mattia Intra MD & Umberto Veronesi MD

  3. Pathology Department, European Institute of Oncology, Milan, Italy

    Giuseppe Viale MD

Authors
  1. Virgilio Sacchini MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefano Zurrida MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gisella Andreoni MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alberto Luini MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Viviana Galimberti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Paolo Veronesi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mattia Intra MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Giuseppe Viale MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Umberto Veronesi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Virgilio Sacchini MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sacchini, V., Zurrida, S., Andreoni, G. et al. Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. Annals of Surgical Oncology 9, 266–271 (2002). https://doi.org/10.1007/BF02573064

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02573064

Key words

Search

Navigation